MONTE ROSA THERAPEUTICS INC Share Price Today: Live Updates & Key Insights

MONTE ROSA THERAPEUTICS INC share price today is $22.7, up -1.09%. The stock opened at $22.96 against the previous close of $23.03, with an intraday high of $24.15 and low of $22.41.

MONTE ROSA THERAPEUTICS INC Share Price Chart

MONTE ROSA THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
us-stock

MONTE ROSA THERAPEUTICS INC Share Price Performance

$22.7 -0.0109(-1.09%) GLUE at 27 Jul 2026 03:19 PM Biotechnology
Lowest Today 22.41
Highest Today 24.15
Today’s Open 22.96
Prev. Close 23.03
52 Week High 25.77
52 Week Low 4.12
Day’s Range: Low 22.41 High 24.15
52-Week Range: Low 4.12 High 25.77
1 day return -
1 Week return -3.23
1 month return +2.2
3 month return +17.92
6 month return +1.42
1 year return +310.83
3 year return +232.26
5 year return -0.52
10 year return -

MONTE ROSA THERAPEUTICS INC Institutional Holdings

NEA Management Company, LLC 9.11

T. Rowe Price Associates, Inc. 7.95

BlackRock Inc 6.67

TCG Crossover Management, LLC 5.47

Bvf Inc 5.28

Baker Bros Advisors LP 5.14

Suvretta Capital Management, LLC 5.00

Vestal Point Capital LP 4.27

State Street Corp 3.97

Vanguard Group Inc 3.84

BRAIDWELL LP 3.80

Versant Venture Management LLC 3.77

Vanguard Capital Management, LLC 3.67

American Century Companies Inc 3.33

Vanguard Total Stock Mkt Idx Inv 3.02

T. Rowe Price New Horizons 2.64

State Street® SPDR® S&P® Biotech ETF 2.49

SILVERARC CAPITAL MANAGEMENT, LLC 2.37

US Small-Cap Growth II Equity Comp 2.35

iShares Russell 2000 ETF 2.30

HBM Healthcare Investments AG Ord 2.16

T. Rowe Price Health Sciences 2.16

Aisling Capital Management LP 1.84

Geode Capital Management, LLC 1.82

Marshall Wace Asset Management Ltd 1.70

T. Rowe Price Integrated US SmCapGrEq 1.63

Avantis US Small Cap Value ETF 1.53

Bellevue Group AG 1.48

MPM Oncology Impact Management LP 1.39

T. Rowe Price New Horizons Tr-A 1.16

Vanguard Institutional Extnd Mkt Idx Tr 0.93

T. Rowe Price Integrated US Sm Gr Eq 0.90

iShares Russell 2000 Growth ETF 0.82

MEDICAL BioHealth EUR Acc 0.81

FIAM Small Cap Core CIT Cl B 0.76

FIAM Small Cap Core Composite 0.76

Fidelity Small Cap Index 0.71

State St Russell Sm/Mid Cp® Indx SL Cl I 0.51

Vanguard Russell 2000 ETF 0.50

iShares Biotechnology ETF 0.50

MONTE ROSA THERAPEUTICS INC Market Status

Strong Buy: 6

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

MONTE ROSA THERAPEUTICS INC Fundamentals

Market Cap 1945.56 M

PB Ratio 3.8507

PE Ratio 0.0

Enterprise Value 1382.61 M

Total Assets 448.66 M

Volume 870562

MONTE ROSA THERAPEUTICS INC Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-132882000 -132.9M, FY22:-104618000 -104.6M, FY21:-71942000 -71.9M, FY20:-36068000 -36.1M, FY19:-8017000 -8.0M

Quarterly Revenue Q1/2026:4210000 4.2M, Q3/2025:12768000 12.8M, Q2/2025:23194000 23.2M, Q1/2025:84929000 84.9M, Q3/2024:9216000 9.2M

Quarterly Profit Q1/2026:2181000 2.2M, Q3/2025:10673000 10.7M, Q2/2025:23194000 23.2M, Q1/2025:84929000 84.9M, Q3/2024:9216000 9.2M

Quarterly Net worth Q1/2026:-44503000 -44.5M, Q3/2025:-27081000 -27.1M, Q2/2025:-12295000 -12.3M, Q1/2025:46885000 46.9M, Q3/2024:-23859000 -23.9M

About MONTE ROSA THERAPEUTICS INC & investment objective

Company Information Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 187

Industry Biotechnology

CEO Dr. Markus Warmuth M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

MONTE ROSA THERAPEUTICS INC FAQs

What is the share price of MONTE ROSA THERAPEUTICS INC today?

The current share price of MONTE ROSA THERAPEUTICS INC is $22.7.

Can I buy MONTE ROSA THERAPEUTICS INC shares in India?

Yes, Indian investors can buy MONTE ROSA THERAPEUTICS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy MONTE ROSA THERAPEUTICS INC shares in India?

You can easily invest in MONTE ROSA THERAPEUTICS INC shares from India by:

Can I buy fractional shares of MONTE ROSA THERAPEUTICS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of MONTE ROSA THERAPEUTICS INC?

MONTE ROSA THERAPEUTICS INC has a market cap of $1945.56 M.

In which sector does MONTE ROSA THERAPEUTICS INC belong?

MONTE ROSA THERAPEUTICS INC operates in the Biotechnology sector.

What documents are required to invest in MONTE ROSA THERAPEUTICS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of MONTE ROSA THERAPEUTICS INC?

The PE ratio of MONTE ROSA THERAPEUTICS INC is N/A and the PB ratio is 3.85.